Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease

Recruiting · NCT07265544 · Observational (researchers observe without assigning treatment) · Lead sponsor: Nanfang Hospital, Southern Medical University

View the official record on ClinicalTrials.gov →

NASH

Interventions studied

Collection of Discarded Liver Tissue During SurgeryCollection of Preoperative Peripheral Blood

What this trial is about

The purpose of this observational study is to employ single-cell multi-omics and spatial omics technologies to characterize the spatial and immune structures within the livers of patients with fatty liver, hepatic hemangioma, focal nodular hyperplasia, liver fibrosis, cirrhosis, and HBV infection. The primary questions it aims to address are: Investigate the mechanisms of liver degenerative changes during the processes of liver aging, fatty liver, HBV infection, liver fibrosis, and cirrhosis. Characterize the molecular features and cellular networks at different stages of liver degeneration and identify new targets and mechanisms for the cure of the aforementioned diseases. The study will collect peripheral blood and discarded liver tissue from patients with hepatic hemangioma, fatty liver, HBV infection, liver fibrosis, and cirrhosis who are undergoing hepatectomy or liver biopsy.

Who can take part

Age range

No age limits stated

Sex

All (male and female)

Healthy volunteers

Yes - healthy volunteers may be accepted

Phase

Not specified

Study type

Observational (researchers observe without assigning treatment)

Inclusion criteria

Voluntarily signed the informed consent form;
No restrictions on age and gender;
Patients diagnosed with hepatic hemangioma or focal nodular hyperplasia of the liver in accordance with the "Guidelines for the Diagnosis and Treatment of Focal Liver Lesions (2014 Edition)" and the "Guidelines for the Diagnosis and Treatment of Hemangiomas and Vascular Malformations (2019 Edition)";
Patients with hepatic hemangioma, focal nodular hyperplasia of the liver, fatty liver, HBV infection, liver fibrosis, and cirrhosis who clinically require liver surgery or liver biopsy.

Exclusion criteria

Individuals with concurrent infections such as HIV will be excluded.
Patients with coagulation system disorders, such as hemophilia or idiopathic thrombocytopenic purpura, will not be included.
Those with severe underlying diseases that affect the body's immune status will be excluded.
Individuals whom the investigator deems unsuitable for participation in this study will be excluded.

Where it is running

1 location listed.

Nan - Guangzhou, Guangdong, China

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →